Novartis AG
NVS
$112.72
$0.840.75%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -66.77% | 81.09% | 40.16% | 17.23% | 478.44% |
| Total Depreciation and Amortization | 110.87% | -11.70% | -11.57% | -16.17% | -218.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 139.83% | -19.38% | 202.69% | -36.51% | -397.57% |
| Change in Net Operating Assets | 65.40% | -10.73% | 73.40% | -22.67% | -654.14% |
| Cash from Operations | 64.63% | 16.88% | 36.33% | -23.40% | -38.04% |
| Capital Expenditure | -37.44% | -22.99% | -15.56% | -35.12% | -32.68% |
| Sale of Property, Plant, and Equipment | -71.34% | -98.04% | 825.00% | -94.44% | 60.78% |
| Cash Acquisitions | -7,000.00% | 98.32% | -3,193.00% | -2,310.00% | -200.00% |
| Divestitures | 8,300.00% | 250.00% | -262.50% | -192.31% | 60.00% |
| Other Investing Activities | -49.67% | -100.21% | 144.79% | -103.65% | -20.22% |
| Cash from Investing | -72.33% | 83.09% | -204.56% | -108.46% | -19.97% |
| Total Debt Issued | -104.40% | -- | -- | 22.12% | 145.65% |
| Total Debt Repaid | -228.13% | 57.10% | -185.40% | -1.52% | 200.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -119.90% | -75.63% | 45.35% | 61.92% | 53.10% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | 28.23% | -- |
| Other Financing Activities | -428.21% | -101.23% | -126.60% | 92.81% | 169.64% |
| Cash from Financing | -393.57% | 54.09% | 12.02% | 43.88% | 84.80% |
| Foreign Exchange rate Adjustments | -296.25% | 206.02% | -3,300.00% | -217.76% | 13.48% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -317.61% | 275.39% | -40.45% | -187.53% | 181.72% |
